Glycemic Control After T1D Onset Associated with Long-Term Diabetic Retinopathy Risk
Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.
Dulaglutide Linked to Improved Glycemic Control in Pediatric Patients with T2D
A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of <7.0% than the placebo group at week 26 of the AWARD-PEDS trial.
Tirzepatide Yields Significant Weight Loss in Patients with Obesity in SURMOUNT-1
Data show the mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg, and -20.9% with 15-mg dose, compared to -3.1% with placebo.
Sarah Bermudez, PharmD: SGLT2 Inhibitors Underutilized in Heart Failure Care
The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.
High Physical Activity Linked to Poor Glycemia Level in Patients with T1D, Obesity
The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.
Time in Hypoglycemia After Exercise Reduced with Insulin Glargine Use in T1D Care
The mean time below range following exercise sessions was significantly lower with IGlar U300 compared to IDEG at the 100% dose.
Oral Semaglutide Effective Real-World Treatment for Patients with T2D, Uncontrolled A1c
The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.
NT-proBNP Serves as Cardiovascular Event, Death Biomarker in Post-ACS Patients with Diabetes
Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.
Effects of Finerenone Not Modified By HbA1c Variability in Patients with CKD, T2D
However, the post-hoc analysis found a greater variability in HbA1c levels was associated with increased risk of cardiorenal outcomes.
Roy Taylor, MD: Using Personal Fat Thresholds to Reach Type 2 Diabetes Remission
The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.
Semaglutide Significantly Reduces Long-Term Diabetes Risk Among Obesity Patients
New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.
Benefit of Finerenone on CV, Kidney Outcomes Not Modified by GLP-1 RA Use
A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.
Dennis Bruemmer, MD: Defining a New Era of Diabetes Care
Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.
New Research Calls for Greater Focus on Food Security in YYA Patients with Diabetes
Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.
Elaine M. Apperson, MD: Discussing Treatment in Pediatric Patients with Type 1 Diabetes
Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.
Canagliflozin Linked to Reduction in Renal, CV Events Across Geographic Regions
Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.
Elena A Christofides, MD: Obesity Management in Type 2 Diabetes Patients
Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.
New Study Seeks to Increase Vaccination Rate in Patients with Type 2 Diabetes
Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine
Elena A Christofides, MD: Perspectives on Risk Factors, Care for Type 1 Diabetes Patients
In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.
Oral Leptin Formulation Offers Short-Term Benefit for Type 1 Diabetes Patients
Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.
COVID-19 Lockdowns Lead to Increase in HbA1c in Diabetes Patients
Changes in physical activity and diet may be main cause for worsening of diabetes control.
COVID-19 Pandemic Associated with Distress in Pediatric Type 1 Diabetes Population
Data show similar family impact and distress scores at baseline and 3-months, highlighting continued impact of COVID-19 on T1D population.
Study Explores Links Between Pediatric Hypoglycemia and Sleep Quality Measures
A longer time spent in hypoglycemia over a 24-hour period was associated with disrupted sleep among children with type 1 diabetes.
Matthew Budoff, MD: Determining Treatment for T2D Patient at Risk of CV Event
Matthew Budoff, MD highlights his own preferred methods of treatment and what might need to be done to help doctors and patients through the process.
Research Shows New FRC Treatment Could Benefit Patients with Type 2 Diabetes
The study shows a reduction in hemoglobin and a reduced risk of hypoglycemia in participants.
New Study Shows the Benefits of Gla-300 Treatment for Type 2 Diabetes Patients
Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.
Dapagliflozin Linked to Reduction in Incidence of Type 2 Diabetes
Data show a 38% reduction in T2D incidence with dapagliflozin compared to placebo in patients with CKD.
Clinical Confidence Increases in Prescribing SGLT2i, GLP-1 for Type 2 Diabetes
Data show 66% of healthcare professionals reported greater confidence in prescribing SGLT2i, while 55% reported greater confidence in prescribing GLP-1.
SGLT2 Inhibitors Increase Risk of Retinal Vein Occlusion
Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.
Empagliflozin Linked to Fluid Reduction in Type 2 Diabetes and CVD Patients
Fluid regulation is important to the prevention of heart failure.
2 Clarke Drive Cranbury, NJ 08512